Literature DB >> 15797051

In-hospital patients exposed to clopidogrel before coronary artery bypass graft surgery: a word of caution.

Raimondo Ascione1, Arup Ghosh, Chris A Rogers, Alan Cohen, Chris Monk, Gianni D Angelini.   

Abstract

BACKGROUND: The aim of our study was to investigate the independent effect of preoperative exposure to aspirin, heparin, and clopidogrel on early clinical outcomes of in-hospital referral patients undergoing first time coronary artery bypass graft (CABG) surgery.
METHODS: Outcomes for in-hospital referrals for CABG between January 2001 and January 2002 were prospectively recorded. Exposure to aspirin, heparin, and clopidogrel during the 5 days before surgery was recorded, and their effect on outcome was explored using multiple regression methods. The effect of clopidogrel given within 48 hours before surgery versus stopped at least 48 hours before the operation was also investigated.
RESULTS: In-hospital referral patients represented 40% (473 of 1,185) of the total surgical population; 304 (64.7%) were prescribed aspirin, 116 (24.7%) heparin, 91 (19.4%) clopidogrel, and 133 (28.3%) had all anticoagulants stopped 5 days before surgery. In-hospital mortality was 2.3% (95% confidence interval [CI]: 1.1 to 4.1) and was highest among those exposed to clopidogrel (odds ratio 16.9, 95% CI: 2.10 to 136, p = 0.008). Seven of the 11 deaths occurred in patients given clopidogrel. Postoperative intraaortic balloon pump, arrhythmia, reintubation, and stroke were all significantly more common when clopidogrel was prescribed (relative risk estimates all greater than 1.5, p values all < or = 0.021). Blood loss was 37% higher in the patients given clopidogrel (95% CI: +3% to +82%, p = 0.033). Clopidogrel patients were more likely to need a reoperation for bleeding (p < 0.001) and require transfusions (p < or = 0.015). Intubation time and hospital stay were also longer (p = 0.021 and p = 0.019, respectively). Heparin was also associated with longer hospital stay (p < 0.001) and aspirin use with reduced stay (p = 0.041), but for all other outcomes, no association with aspirin or heparin use was found. Comparison of subgroups of clopidogrel patients suggested mortality was highest when clopidogrel was given in the 48 hours before surgery.
CONCLUSIONS: Our study suggests that among in-hospital referral patients, preoperative exposure to clopidogrel within 5 days before CABG may increase early mortality and morbidity, and that the mortality risk is greatest when the drug is given within 48 hours of surgery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15797051     DOI: 10.1016/j.athoracsur.2004.09.046

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  15 in total

Review 1.  [Coronary stents, dual antiplatelet therapy and peri-operative problems].

Authors:  H Metzler; K Huber; S Kozek-Langenecker; M N Vicenzi; A Münch
Journal:  Anaesthesist       Date:  2007-04       Impact factor: 1.041

2.  Simultaneous "hybrid" percutaneous coronary intervention and minimally invasive surgical bypass grafting: feasibility, safety, and clinical outcomes.

Authors:  Barry Reicher; Robert S Poston; Mandeep R Mehra; Ashish Joshi; Patrick Odonkor; Zachary Kon; Peter A Reyes; David A Zimrin
Journal:  Am Heart J       Date:  2008-03-05       Impact factor: 4.749

Review 3.  Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics.

Authors:  Charles Brown; Brijen Joshi; Nauder Faraday; Ashish Shah; David Yuh; Jeffrey J Rade; Charles W Hogue
Journal:  Anesth Analg       Date:  2011-03-08       Impact factor: 5.108

4.  Blood management-issues: the panic of coagulopathic bleeding--is there a rational approach?

Authors:  Bruce D Spiess
Journal:  J Extra Corpor Technol       Date:  2011-03

5.  Risk stratification in acute coronary syndromes.

Authors:  Gabriele Pesarini; Francesco Santini; Giulia Geremia; Carlo Zivelonghi; Flavio Ribichini
Journal:  J Cardiovasc Transl Res       Date:  2011-12-02       Impact factor: 4.132

6.  Clopidogrel (PLAVIX) increases risk of bleeding in a patient undergoing coronary artery bypass grafting.

Authors:  Hitoshi Hirose
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2006-09

Review 7.  Clopidogrel: a review of its use in the prevention of thrombosis.

Authors:  Greg L Plosker; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28.

Authors:  Dalton S McLean; Marc S Sabatine; Wei Guo; Carolyn H McCabe; Christopher P Cannon
Journal:  J Thromb Thrombolysis       Date:  2007-02-24       Impact factor: 2.300

9.  Point-of-care platelet function testing predicts bleeding in patients exposed to clopidogrel undergoing coronary artery bypass grafting: Verify pre-op TIMI 45--a pilot study.

Authors:  Grant W Reed; Amit Kumar; Jianping Guo; Sary Aranki; Prem Shekar; Arvind Agnihotri; Andrew O Maree; Dalton S McLean; Kenneth Rosenfield; Christopher P Cannon
Journal:  Clin Cardiol       Date:  2015-02-05       Impact factor: 2.882

10.  Predicting Likelihood for Coronary Artery Bypass Grafting After Non-ST-Elevation Myocardial Infarction: Finding the Best Prediction Model.

Authors:  Ali Shafiq; Jae-Sik Jang; Faraz Kureshi; Timothy J Fendler; Kensey Gosch; Phil G Jones; David J Cohen; Richard Bach; John A Spertus
Journal:  Ann Thorac Surg       Date:  2016-06-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.